Rasonque Approval Triggers Expanded Access Closures, Delaying Coverage for Metastatic Pancreatic Cancer Patients by Weeks

The STAT investigation details how regulatory approval immediately ended pre-approval compassionate use for Rasonque, a KRAS-targeted agent, while Medicare Part D plans and PBMs like OptumRx required additional weeks for formulary listing and prior authorization processing. One Medicare denial cited incomplete FDA listing, resolved only after public pressure. Similar transitional gaps have followed approvals of other targeted oncology agents.

Observational data from PanCAN and clinician reports at St. Luke’s show at least several dozen patients affected in the first month post-approval, with stage 4 cases progressing during delays. This pattern mirrors documented access lags after 2023-2024 KRAS inhibitor launches, where median time to commercial coverage reached 45 days in Medicare cohorts. The mechanism is structural: FDA action ends sponsor programs before payers complete coding and evidence reviews.

Analysis of the Solano case and Loaiza-Bonilla’s X-post incident reveals how aggressive tumors leave no buffer for administrative friction, unlike slower-progressing malignancies. Prior observational studies in JAMA Internal Medicine on compassionate-use closures confirm higher dropout rates when approval precedes payer readiness, particularly for drugs lacking immediate compendia inclusion.

Next steps require sponsors to maintain limited post-approval bridging programs or FDA-mandated transition timelines; without policy change, recurrence is likely with future accelerated approvals in pancreatic cancer.